Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatocellular CarcinomaLenvatinibTislelizumabTACEPharmorubicinOxaliplatin

Interventions

PROCEDURE

TACE

TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.

DRUG

Tislelizumab, Lenvatinib

Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.

Trial Locations (1)

RECRUITING

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER